Non-Competes Eased, Anti-DEI Rule Blocked, Contractor Rule in Limbo - Employment Law This Week® - #WorkforceWednesday®
Clocking in with PilieroMazza: Latest Developments on DEI Executive Order and Action Items before April 21 Deadline
2 Gurus Talk Compliance: Episode 49 - The Depression Episode
072: Prepare For Trump Executive Orders To Hit Your Law Firm
#WorkforceWednesday®: EEOC/DOJ Joint DEI Guidance, EEOC Letters to Law Firms, OFCCP Retroactive DEI Enforcement - Employment Law This Week®
#WorkforceWednesday®: Federal Contractors Alert - DEI Restrictions Reinstated by Appeals Court - Employment Law This Week®
State AG Pulse | DEI in the Federal and State Spotlight
ESG Essentials: What You Need To Know Now - Episode 18 - The Reshaping of ESG & DEI
#WorkforceWednesday®: Should Employers Shift Workforce Data Collection Under President Trump? - Employment Law This Week®
When DE&I Are Under Attack: On Record PR
AGG Talks: Solving Employers’ Problems Podcast - Episode 5: What Employers Need to Know About DEI Policy Changes Under the Trump Administration
#WorkforceWednesday®: Workplace Law Shake-Up - DEI Challenges, NLRB Reversals, and EEOC Actions - Employment Law This Week®
False Claims Act Insights - Can DE&I Initiatives Lead to Potential False Claims Act Liability?
Terra Davis of Knobbe Martens on Fostering Psychological Safety, Inclusion and Belonging - CMO Series REPRESENTS Podcast
Understanding the New DEI Executive Order: What's the Tea in L&E?
Lynnette Espy-Williams of Cozen O’Connor on Thriving Together: Cultivating Allyship, Safety & Diversity in Law Firm Culture - CMO Series REPRESENTS Re-release
Diana Lauritson of Hogan Lovells on Color, Culture, and Leadership: Raising the Next Generation of Marketing Leaders - CMO Series REPRESENTS
Flipping the Script on DEI: Courtney Carter of Jenner & Block on Developing Talent and Shaping Client Relationships - CMO Series Podcast RE-RELEASE
What to Expect from the New FTC Leadership
Employment Law Now VIII-158 - DEI Developments and Executive Coaching
For more than a decade, the Food and Drug Administration (FDA) has made diversity in clinical trials a focus, including by issuing guidance, convening public-private workshops, and completing data analyses in an effort to...more
The U.S. Food and Drug Administration (FDA) has demonstrated a commitment to expanding diversity in clinical trials. Decentralized Clinical Trials ( DCTs) contribute to this effort by enhancing convenience for trial...more
The Food and Drug Administration (FDA) has issued new draft guidance, Postmarketing Approaches to Obtain Data on Populations Underrepresented in Clinical Trials for Drugs and Biological Products (the Draft Postmarketing...more